Plans to roll out a "revolutionary" breast cancer drug across the UK are "a huge step forward", according to health campaigners.
Kadcyla will be available on the cancer drugs fund, a move which will make "a significant difference" to breast cancer sufferers who have stopped responding to chemo, according to Dr Caitlin Palframan.
Kadcyla has been shown to extend life by up to six months in HER2-positive secondary breast cancer patients, and with more manageable side effects than alternative drugs.
It has the potential to provide women with a better quality of life in their final months than existing treatments, which could make a significant difference.
A thousand women die from metastatic, or secondary, breast cancer every month in the UK and this treatment has the potential to provide some of them not only with additional time, but importantly, quality time to spend with their friends and families.
More top news
On Monday afternoon, numerous Facebook posts claimed a silver Mini had been stolen from the town with a girl in it.
Top temperatures 10 Celsius (50F).
Britain and the European Commission reached agreement on a transition deal which will allow talks on the future trade relationship.